Dopharma and Ripac-Labor Celebrate Topping-Out Ceremony for New Production Facility for Autogenous Vaccines in Potsdam
Raamsdonksveer, Netherlands / Potsdam, Germany, April 1, 2026 – In the presence of the Mayor of the City of Potsdam, Ms. Noosha Aubel, the Dopharma Group and its wholly owned subsidiary Ripac-Labor GmbH celebrated the topping-out ceremony for their new, state-of-the-art production facility for autogenous vaccines.
With this construction project, the company is laying the foundation for its long-term establishment in the region. The production facility is specifically designed for the manufacture of autogenous vaccines and is being built at a time of significant regulatory developments at both European and national levels. These changes aim to harmonize the requirements for Good Manufacturing Practice (GMP) for these specialized veterinary medicinal products across Europe.
Ahead of European Legislation
Although EU legislation has not yet been officially adopted, the Dopharma Group and Ripac-Labor remain committed to their responsibility. This means continuing to invest in the future of autogenous vaccines and consistently driving this ambitious project forward.
“The Dopharma Group firmly believes that autogenous vaccines will play a crucial role in livestock farming in ensuring the health of agricultural animals,” emphasizes Wijnand de Bruijn, CEO Business of the Dopharma Group. “With the new production facility, we are setting benchmarks in quality and innovation. It will be among the most modern facilities of its kind in Europe and will make an important contribution to the sustainable development of our company.”
Commissioning Planned for the End of 2026
The investment project underscores the company’s commitment to innovation, animal health, and future-proof, sustainable agricultural production. Thanks to the proven fast-track approach of the general planner PBM gr.up GmbH, commissioning of the new production facility is already scheduled for the end of 2026.
Press contact: For media inquiries, please contact: communication@dopharma.com.
Downloads: Download the press release as a PDF
About Ripac-Labor GmbH
Ripac-Labor GmbH, a wholly owned subsidiary of Dopharma International B.V., specializes in veterinary diagnostics as well as the production of autogenous vaccines for livestock. These individually tailored vaccines provide targeted protection against farm-specific pathogens and are an essential tool for the prevention and control of infectious diseases. By expanding its production capacities, Ripac-Labor strengthens the market position of the Dopharma Group in the European veterinary pharmaceutical market. Currently, nearly 50 academic specialists, experienced laboratory technicians, and other highly qualified staff are employed at the company.
About the Dopharma Group
Dopharma is a family-owned pharmaceutical company that has been developing and producing high-quality veterinary medicinal products for livestock since 1969. 95% of its veterinary products are manufactured in the company’s GMP-certified production facilities, ensuring the highest quality standards and continuous innovation. Dopharma’s mission is to support the health and productivity of livestock worldwide through scientifically grounded solutions.
